MannKind Corp (MNKD) stock
MNKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30119% above fair value
$4.07+0.00 (0.00%)
Close on Nov 18, 2026Market cap $1.31BP/E –Yield –
MannKind shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
MannKind's shares outstanding was 309M at Jun 30, 2026. For fiscal 2025 it was 314M, up 10.7% from the year before. Over ten years it grew 14.5% a year on average. The highest annual figure on record is 314M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 314M | +10.7% |
| FY2024 | Dec 31, 2024 | 284M | +6.3% |
| FY2023 | Dec 31, 2023 | 267M | +3.9% |
| FY2022 | Dec 31, 2022 | 257M | +3.1% |
| FY2021 | Dec 31, 2021 | 249M | +12.0% |
| FY2020 | Dec 31, 2020 | 223M | +13.8% |
| FY2019 | Dec 31, 2019 | 196M | +35.7% |
| FY2018 | Dec 31, 2018 | 144M | +38.3% |
| FY2017 | Dec 31, 2017 | 104M | +13.2% |
| FY2016 | Dec 31, 2016 | 92M | +13.4% |
| FY2015 | Dec 31, 2015 | 81M | +5.4% |
| FY2014 | Dec 31, 2014 | 77M | +28.6% |
| FY2013 | Dec 31, 2013 | 60M | +65.7% |
| FY2012 | Dec 31, 2012 | 36M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 309M | -0.7% |
| Q1 FY2026 | Mar 31, 2026 | 308M | -3.9% |
| Q4 FY2025 | Dec 31, 2025 | 316M | +8.7% |
| Q3 FY2025 | Sep 30, 2025 | 312M | +9.5% |
| Q2 FY2025 | Jun 30, 2025 | 311M | +14.1% |
| Q1 FY2025 | Mar 31, 2025 | 321M | -1.2% |
| Q4 FY2024 | Dec 31, 2024 | 291M | +8.0% |
| Q3 FY2024 | Sep 30, 2024 | 285M | -12.1% |
| Q2 FY2024 | Jun 30, 2024 | 273M | +2.8% |
| Q1 FY2024 | Mar 31, 2024 | 325M | +23.0% |
| Q4 FY2023 | Dec 31, 2023 | 270M | +2.4% |
| Q3 FY2023 | Sep 30, 2023 | 324M | +24.9% |
| Q2 FY2023 | Jun 30, 2023 | 266M | +4.7% |
| Q1 FY2023 | Mar 31, 2023 | 264M | +4.8% |
| Q4 FY2022 | Dec 31, 2022 | 263M | +4.9% |
| Q3 FY2022 | Sep 30, 2022 | 259M | +3.8% |
| Q2 FY2022 | Jun 30, 2022 | 254M | +1.7% |
| Q1 FY2022 | Mar 31, 2022 | 252M | +2.1% |
| Q4 FY2021 | Dec 31, 2021 | 251M | +7.0% |
| Q3 FY2021 | Sep 30, 2021 | 250M | +8.8% |
| Q2 FY2021 | Jun 30, 2021 | 249M | +16.6% |
| Q1 FY2021 | Mar 31, 2021 | 247M | +16.1% |
| Q4 FY2020 | Dec 31, 2020 | 235M | +13.5% |
| Q3 FY2020 | Sep 30, 2020 | 230M | +14.9% |
| Q2 FY2020 | Jun 30, 2020 | 214M | +13.7% |
| Q1 FY2020 | Mar 31, 2020 | 212M | +13.4% |
| Q4 FY2019 | Dec 31, 2019 | 207M | +28.1% |
| Q3 FY2019 | Sep 30, 2019 | 200M | +30.1% |
| Q2 FY2019 | Jun 30, 2019 | 188M | +34.3% |
| Q1 FY2019 | Mar 31, 2019 | 187M | +55.0% |
| Q4 FY2018 | Dec 31, 2018 | 161M | +38.6% |
| Q3 FY2018 | Sep 30, 2018 | 154M | +46.7% |
| Q2 FY2018 | Jun 30, 2018 | 140M | +40.2% |
| Q1 FY2018 | Mar 31, 2018 | 121M | +26.3% |
| Q4 FY2017 | Dec 31, 2017 | 116M | +20.7% |
| Q3 FY2017 | Sep 30, 2017 | 105M | +8.4% |
| Q2 FY2017 | Jun 30, 2017 | 100M | – |
| Q1 FY2017 | Mar 31, 2017 | 96M | – |
| Q4 FY2016 | Dec 31, 2016 | 97M | – |
| Q3 FY2016 | Sep 30, 2016 | 97M | – |
See a number that looks wrong?